Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Other Operating Expenses (2021 - 2025)

Historic Other Operating Expenses for Oncology Institute (TOI) over the last 5 years, with Q3 2025 value amounting to $118.4 million.

  • Oncology Institute's Other Operating Expenses rose 3713.79% to $118.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $395.8 million, marking a year-over-year increase of 2055.79%. This contributed to the annual value of $342.5 million for FY2024, which is 2037.24% up from last year.
  • Latest data reveals that Oncology Institute reported Other Operating Expenses of $118.4 million as of Q3 2025, which was up 3713.79% from $103.1 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Other Operating Expenses registered a high of $118.4 million during Q3 2025, and its lowest value of $39.0 million during Q1 2021.
  • In the last 5 years, Oncology Institute's Other Operating Expenses had a median value of $66.8 million in 2023 and averaged $69.2 million.
  • In the last 5 years, Oncology Institute's Other Operating Expenses skyrocketed by 8314.03% in 2023 and then surged by 474.73% in 2024.
  • Oncology Institute's Other Operating Expenses (Quarter) stood at $44.6 million in 2021, then soared by 48.94% to $66.5 million in 2022, then grew by 8.59% to $72.2 million in 2023, then rose by 19.71% to $86.4 million in 2024, then surged by 36.98% to $118.4 million in 2025.
  • Its Other Operating Expenses stands at $118.4 million for Q3 2025, versus $103.1 million for Q2 2025 and $87.9 million for Q1 2025.